Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.

Felger JC, Treadway MT.

Neuropsychopharmacology. 2017 Jan;42(1):216-241. doi: 10.1038/npp.2016.143. Epub 2016 Aug 2.

PMID:
27480574
2.

Pharmacological treatments for fatigue associated with palliative care: executive summary of a Cochrane Collaboration systematic review.

Mücke M, Mochamat, Cuhls H, Peuckmann-Post V, Minton O, Stone P, Radbruch L.

J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):23-7. doi: 10.1002/jcsm.12101. Epub 2016 Feb 10. Review.

3.

Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program.

Roth ME, O'Mara AM, Seibel NL, Dickens DS, Langevin AM, Pollock BH, Freyer DR.

J Oncol Pract. 2016 Apr;12(4):e388-95. doi: 10.1200/JOP.2015.009084. Epub 2016 Mar 29.

4.

Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses.

Morris G, Berk M, Walder K, Maes M.

BMC Med. 2015 Feb 6;13:28. doi: 10.1186/s12916-014-0259-2. Review.

5.

A Brief Patient Self-Report Screening Measure of Cancer Treatment-Related Memory Problems: Latent Structure and Reliability Analysis.

Jean-Pierre P, Morrow GR, Mohile SG, Stevenson J, Fiscella K, Griggs JJ, Roscoe JA, Carroll J, Singh D, Atkins J, Khanna R.

Treat Strateg Oncol. 2011;2(1):93-95.

6.

Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue.

Norden DM, Devine R, Bicer S, Jing R, Reiser PJ, Wold LE, Godbout JP, McCarthy DO.

Physiol Behav. 2015 Mar 1;140:230-5. doi: 10.1016/j.physbeh.2014.12.045. Epub 2014 Dec 30.

7.

Cancer-related and treatment-related fatigue.

Wang XS, Woodruff JF.

Gynecol Oncol. 2015 Mar;136(3):446-52. doi: 10.1016/j.ygyno.2014.10.013. Epub 2014 Oct 23. Review.

8.

PURLs: Finally, a way to relieve cancer-related fatigue.

Thomas GB, Asher GN, Mounsey A.

J Fam Pract. 2014 May;63(5):270-2. No abstract available.

9.

Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation.

Russi EG, Raber-Durlacher JE, Sonis ST.

Mediators Inflamm. 2014;2014:518261. doi: 10.1155/2014/518261. Epub 2014 Mar 16.

10.

Predictors of significant worsening of patient-reported fatigue over a 1-month timeframe in ambulatory patients with common solid tumors.

Fisch MJ, Zhao F, O'Mara AM, Wang XS, Cella D, Cleeland CS.

Cancer. 2014 Feb 1;120(3):442-50. doi: 10.1002/cncr.28437. Epub 2013 Oct 21.

11.

Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.

Rondanelli M, Faliva MA, Perna S, Antoniello N.

Aging Clin Exp Res. 2013 Oct;25(5):499-510. doi: 10.1007/s40520-013-0118-6. Epub 2013 Sep 18. Review.

12.

Aiming for a better understanding and management of cancer-related fatigue.

Neefjes EC, van der Vorst MJ, Blauwhoff-Buskermolen S, Verheul HM.

Oncologist. 2013;18(10):1135-43. doi: 10.1634/theoncologist.2013-0076. Epub 2013 Sep 13. Review.

13.

Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2.

Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, McGinn TW, Stella PJ, Seeger GR, Sood A, Loprinzi CL.

J Natl Cancer Inst. 2013 Aug 21;105(16):1230-8. doi: 10.1093/jnci/djt181. Epub 2013 Jul 13.

14.

Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis.

Laoutidis ZG, Mathiak K.

BMC Psychiatry. 2013 May 16;13:140. doi: 10.1186/1471-244X-13-140. Review.

15.

Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Felger JC, Lotrich FE.

Neuroscience. 2013 Aug 29;246:199-229. doi: 10.1016/j.neuroscience.2013.04.060. Epub 2013 May 3. Review.

16.

Lagged relationships among sleep disturbance, fatigue, and depressed mood during chemotherapy.

Jim HS, Jacobsen PB, Phillips KM, Wenham RM, Roberts W, Small BJ.

Health Psychol. 2013 Jul;32(7):768-74. doi: 10.1037/a0031322. Epub 2013 Feb 25.

17.

Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment.

Lotrich FE, Albusaysi S, Ferrell RE.

Neuropsychopharmacology. 2013 May;38(6):985-95. doi: 10.1038/npp.2012.263. Epub 2012 Dec 18.

18.

Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations.

Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL, Miller AH.

Brain Behav Immun. 2013 Jul;31:153-60. doi: 10.1016/j.bbi.2012.10.010. Epub 2012 Oct 13.

19.

Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Felger JC, Miller AH.

Front Neuroendocrinol. 2012 Aug;33(3):315-27. doi: 10.1016/j.yfrne.2012.09.003. Epub 2012 Sep 21. Review.

20.

Longitudinal relationships between fatigue and depression in cancer patients with depression and/or pain.

Brown LF, Rand KL, Bigatti SM, Stewart JC, Theobald DE, Wu J, Kroenke K.

Health Psychol. 2013 Dec;32(12):1199-208. doi: 10.1037/a0029773. Epub 2012 Aug 27.

Supplemental Content

Support Center